Medtronic expands AiBLE™ spine surgery ecosystem with new technologies and Siemens Healthineers partnership
GALWAY, Ireland and CHICAGO, Sept. 25, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced...
Brain
InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia
Lille, September 25, 2024 - InBrain Pharma, a biopharmaceutical company specialized in neurodegenerative diseases, will present the positive results of its...
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE)...
FONDAZIONE PRADA PRESENTS “PRESERVING THE BRAIN: A CALL TO ACTION” IN MILAN
MILAN, Sept. 25, 2024 /PRNewswire/ -- The new edition of "Preserving the Brain," part of Fondazione Prada's "Human Brains" project...
IRLAB Presents at the International Congress of Parkinson’s Disease and Movement Disorders(R)(MDS) 2024
GOTHENBURG, SE / ACCESSWIRE / September 25, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 25, 2024 - IRLAB Therapeutics...
BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING
MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going...
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurologySOUTH SAN FRANCISCO, Calif.,...
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase...
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including...
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS...
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in...
Epilepsy Foundation Introduces New Mission & Vision Statements at National Leadership Conference
The New Statements Guide the Foundation’s 2025-2028 Strategic PlanBOWIE, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- After more than 50...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific...
Global Ultrasound Institute Launches GUSI Fellowships Platform: Elevating Point-of-Care Ultrasound Education
SAN FRANCISCO, Sept. 20, 2024 /PRNewswire/ -- The Global Ultrasound Institute (GUSI) is proud to announce the launch of the...
EEG and EMG Devices Market to Grow by USD 793.5 Million (2024-2028) as Rising Neurological Conditions Drive Demand, AI Impact on Market Trends – Technavio Report
NEW YORK, Sept. 20, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global EEG and EMG devices...
Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it...
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase...